trifluridine + tipiracil + anlotinib

This drug is a combination of three small molecules: trifluridine, tipiracil (together known as TAS-102), and anlotinib. Trifluridine is a nucleoside analog that incorporates into DNA, causing DNA dysfunction and inhibiting tumor cell proliferation. Tipiracil inhibits thymidine phosphorylase, preventing the degradation of trifluridine and increasing its bioavailability and cytotoxicity. Anlotinib is a multi-targeted tyrosine kinase inhibitor that blocks vascular endothelial growth factor receptors (VEGFR 1/2/3), fibroblast growth factor receptors (FGFR 1–4), platelet-derived growth factor receptors (PDGFR α/β), and c-Kit, thereby inhibiting angiogenesis and tumor cell proliferation. This combination has been explored as a third-line treatment for metastatic colorectal cancer after failure of standard therapies[1][3]. Early clinical evidence suggests promising efficacy with manageable toxicity in this setting[1].

Brand names

Lonsurf + Fukanghua

Other names

TAS-102 + anlotinibtrifluridine/tipiracil + anlotinib